The clearance represents an expansion beyond the St. Paul, Minn.–based contract manufacturer’s traditional offerings.
“This extension of our business represents an additional way to partner with customers. We have the opportunity to offer them products they can integrate into their own portfolios and bring to market,” Minnetronix Medical CEO Jeremy Maniak said in a statement provided to Medical Design & Outsourcing.
Minnetronix Medical touts the MindsEye Port as the first minimally invasive, expandable port designed for use in the treatment of stroke, cancer and other conditions. The device’s dynamic retraction enables creation of a custom-sized channel for surgeons to reach areas deep within the brain.
Mario Zuccarello, professor of neurosurgery at the University of Cincinnati Medical Center, described the MindsEye as the “next-generation deep brain access technology.”
“Minimizing invasiveness as much as possible is important to respect the eloquence of brain tissue. The MindsEye expandable port allows surgeons to work without unnecessary distractions, which ultimately improves quality of life for the patient,” Zuccarello said in a news release.
The port is already attracting interest among neurosurgeons and potential distribution partners, according to Matt Adams, VP and GM at Minnetronix Medical. “The MindsEye Port is an exciting example of how Minnetronix Medical is expanding its offerings by developing market-ready products,” Adams said.
The port represents an entire platform for the company, according to Adams, as it has additional applications and complementary product opportunities in the neurology market and beyond.